Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
33 hedge funds and large institutions have $180M invested in Harpoon Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 2 reducing their positions, and 3 closing their positions.
650% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 2
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
41% more capital invested
Capital invested by funds: $128M → $180M (+$52.2M)
14% more funds holding
Funds holding: 29 → 33 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.34M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.76M |
| 3 |
State Street
Boston,
Massachusetts
|
+$966K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$502K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$272K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.29M |
| 2 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$421K |
| 3 |
Goldman Sachs
New York
|
-$278K |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$278K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
HARP Hedge Fund Activity: Q2 2019 in Review
33 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q2 2019, worth a combined $180M — up 41% from $128M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new HARP positions and 3 closed out — a net gain of 4 holders — while 15 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock, adding an estimated $2.34M. The largest seller was Millennium Management, cutting an estimated $1.29M.
- 33 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q2 2019, up from 29 in Q1 2019.
- Funds reported $180M of Harpoon Therapeutics, Inc. Common Stock stock for Q2 2019, up 41% quarter-over-quarter.
- 7 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q2 2019 and 3 closed out, a net change of +4 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q2 2019 was BlackRock, an estimated $2.34M added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q2 2019 was Millennium Management, an estimated $1.29M sold.
Based on aggregated 13F filings for Q2 2019.